COVID-19: diabetes perspective—pathophysiology and management
Recent evidence relating to the impact of COVID-19 on people with diabetes is limited but
continues to emerge. COVID-19 pneumonia is a newly identified illness spreading rapidly …
continues to emerge. COVID-19 pneumonia is a newly identified illness spreading rapidly …
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
S Schlesinger, A Lang, N Christodoulou, P Linnerz… - Diabetologia, 2023 - Springer
Aims/hypothesis To provide a systematic overview of the current body of evidence on high-
risk phenotypes of diabetes associated with COVID-19 severity and death. Methods This is …
risk phenotypes of diabetes associated with COVID-19 severity and death. Methods This is …
Type 2 diabetes mellitus and COVID-19: a narrative review
C Rey-Reñones, S Martinez-Torres, FM Martín-Luján… - Biomedicines, 2022 - mdpi.com
Type-2 diabetes mellitus (T2DM) is a chronic metabolic disorder. The incidence and
prevalence of patients with T2DM are increasing worldwide, even reaching epidemic values …
prevalence of patients with T2DM are increasing worldwide, even reaching epidemic values …
Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes …
Background Impaired respiratory function remains underrecognized in patients with type 2
diabetes (T2D), despite common pulmonary impairment. Meanwhile, there is little data …
diabetes (T2D), despite common pulmonary impairment. Meanwhile, there is little data …
COVID‐19 vaccines and their underbelly: Are we going the right way?
Background Historically, a critical aetiological agent of health concern stays till eternity after
its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a …
its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a …
Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases
N Perakakis, H Harb, BG Hale, Z Varga… - The Lancet Diabetes & …, 2023 - thelancet.com
Viruses have been present during all evolutionary steps on earth and have had a major
effect on human history. Viral infections are still among the leading causes of death. Another …
effect on human history. Viral infections are still among the leading causes of death. Another …
Recent research advances in metabolism, clinical and experimental
C Boutari, M Kokkorakis, K Stefanakis… - Metabolism, 2023 - Elsevier
Metabolic disorders such as obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and non-
alcoholic fatty liver disease (NAFLD)–henceforth named metabolic dysfunction-associated …
alcoholic fatty liver disease (NAFLD)–henceforth named metabolic dysfunction-associated …
Protective effects of home T2DM treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors against intensive care unit …
Introduction Type 2 diabetes mellitus (T2DM) is a relevant risk factor for severe forms of
COVID-19 (SARS coronavrus 2 [SARS-CoV-2] disease 2019), and calls for caution because …
COVID-19 (SARS coronavrus 2 [SARS-CoV-2] disease 2019), and calls for caution because …
Diabetic endothelial microangiopathy and pulmonary dysfunction
L Zhang, F Jiang, Y Xie, Y Mo, X Zhang… - Frontiers in …, 2023 - frontiersin.org
Type 2 diabetes mellitus (T2DM) is a widespread metabolic condition with a high global
morbidity and mortality rate that affects the whole body. Their primary consequences are …
morbidity and mortality rate that affects the whole body. Their primary consequences are …
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors and COVID-19 outcomes
A Foresta, L Ojeda-Fernandez, G Macaluso… - Clinical Therapeutics, 2023 - Elsevier
Purpose: It has been reported that dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like
peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors …
peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors …